Heat Biologics, Inc. announced that it has dosed its first patient in its Phase 2 clinical trial investigating HS-110 in combination with Merck's anti-PD1 checkpoint inhibitor, KEYTRUDA (pembrolizumab), in patients with advanced non-small cell lung cancer (NSCLC). This expansion of the company's Phase 2 trial into first-line maintenance treatment with Keytruda follows positive interim results reported last year on previously treated patients receiving HS-110 in combination with Bristol-Myers Squibb's anti-PD-1 checkpoint inhibitor, Opdivo (nivolumab). Heat will continue to dose patients with HS-110 in combination with Opdivo as well. The Company amended its Phase 2 master protocol to include additional patient cohorts in the front-line maintenance setting for advanced NSCLC. Patients in these cohorts will have received a minimum of 9 weeks of pembrolizumab, with or without chemotherapy, and will begin maintenance treatment receiving HS-110 with embrolizumab pemetrexed. Patients will be evaluated for objective response rate as well as progression-free and overall survival.